Overview

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to provide treatment to patients who have participated on a prior protocol investigating Tanespimycin (KOS-953,17-AAG)
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb